Elixinol Global Limited Annual Report 2020

Operations & Financials Overview COMPANY OVERV I EW Annualised cost base 45 % Substantial operational and corporate cost reduction program completed in June 2020. Well funded** 37 % Cash reserves boosted by heavily oversubscribed capital raise provides new funding of $20.5m. $ 27.7 m vs $20.2m in FY2019 -16 -14 -12 -10 -8 -6 -4 -2 0 H1 FY2019 H2 FY2019 H1 FY2020 H2 FY2020 (11.1) (13.5) (14.8) (8.1) Europe Australia Americas Corporate Adjusted EBITDA* Improved significantly between H1 and H2, despite lower revenues with a reduced cost base supporting a simplified strategy. Cost reduction program and higher margin business driving performance improvements. Adjusted EBITDA by Half A$ million, 31 December year end 0 5 10 15 20 25 30 35 FY2019 30.8 15.0 FY2020 Hemp Foods Australia Elixinol e-commerce Elixinol retail Bulk Private label Revenue by channel Divested low margin business to focus on higher margin Elixinol branded products. Driving margin improvement as business mix shifts towards branded consumer goods channels. Revenue by Channel A$ million, 31 December year end 19.6 (64%) 13.5 (90%) * Excluding non-cash impairments ** Cash and cash equivalents at the end of the financial year Company Overview Financial Report Shareholder Information 3 FY2020 Milestones Strategy and Market Update